Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2023-05-09 Board/Management Inform…
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Alia Therapeutic appoints Board Director
Board/Management Information Classification · 98% confidence The document is a press release announcing the appointment of Adel Nada as an Independent Board Director for Alia Therapeutics. It is distributed via RNS (London Stock Exchange's distribution service) and explicitly mentions 'RNS Number : 6702Y'. The content focuses entirely on management/board changes, which aligns with the 'Board/Management Information' definition. Although it is a management announcement, the presence of the RNS header and the nature of the announcement (a significant personnel change) strongly suggests classification as Board/Management Information (MANG). It is not a general regulatory filing (RNS) because MANG is more specific. It is not a DEF 14A as that is specifically for remuneration.
2023-05-09 English
Alia Therapeutics names Letizia Goretti as CEO
Board/Management Information Classification · 98% confidence The document is a press release distributed via RNS (London Stock Exchange's distribution service) announcing a significant management change: the appointment of Letizia Goretti as Chief Executive Officer (CEO) and Board Director of Alia Therapeutics. This directly aligns with the definition for Board/Management Information (MANG). Although it is distributed via RNS, the core content is a management announcement, not a general regulatory filing or a report publication announcement.
2023-05-05 English
Kallelse till årsstämma i Calliditas Therapeutics AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Calliditas Therapeutics AB (publ)" which translates to "Notice of Annual General Meeting in Calliditas Therapeutics AB (publ)". It details the date, location, registration procedures, agenda items (including election of directors, approval of remuneration report, and proposals for share capital changes), and voting rights for the meeting. This content is characteristic of a formal notice and materials related to an Annual General Meeting (AGM). Although it contains proposals that might appear in other filings, the primary purpose and structure align perfectly with AGM documentation. Therefore, the classification is AGM-R.
2023-04-28 Swedish
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of annual general meeting of Calliditas Therapeutics AB (publ)" and details the date, location, registration procedures, agenda items (including election of directors, approval of financial statements, and authorization for share issues), and proposals related to the meeting. This content is the core material for convening and conducting an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length is substantial (over 50,000 characters), confirming it is the primary material, not just an announcement of the meeting.
2023-04-28 English
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-04-26 Swedish
Alia Therapeutics Secures €4.4 Million Financing
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number (4785W) and contains a press release format announcing that 'Alia Therapeutics Secures €4.4 Million Seed Financing Extension'. This clearly relates to a capital-raising or financing activity. The definition for Capital/Financing Update (CAP) covers 'Updates on company fundraising, financing activities, or capital structure changes.' Although it is distributed via RNS, the core content is a financing announcement, making CAP the most specific classification. It is not a full regulatory report (like 10-K or IR) nor a general regulatory filing (RNS) since a more specific category exists.
2023-04-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.